



Enquiries: <u>Stock queries:</u> Ms Babalwa Melitafa E-mail: <u>Babalwa.Melitafa@health.gov.za</u>

<u>Clinical queries:</u> Essential Drugs Programme E-mail: <u>SAEDP@health.gov.za</u>

NOTICE: STREPTOKINASE 1 500 000 IU INJECTION DISCONTINUATION

The Primary Healthcare Level and Adult Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) currently recommends streptokinase in the management of myocardial infarction. The contracted supplier for streptokinase has indicated that the product on contract has been discontinued with immediate effect, and a new formulation of streptokinase will only be available once approval by SAHPRA has been received.

Until supply of streptokinase again becomes available the following alternative recommendation (as per table below) may be considered. Refer to the Primary Healthcare STGs and EML, 2020; and Adult Hospital Level STGs and EML, 2019; for the complete treatment guidance.

Indication: Primary Healthcare Level STGs and EML, 2020	Current recommendation in STGs and EML	Therapeutic alternative
4.4 Myocardial Infarction, Acute (AMI)/ST Elevation Myocardial Infarction (STEMI) - Before transfer FOR URGENT REFERRAL TO NEXT LEVEL OF CARE	 Thrombolytic, (Doctor initiated) Streptokinase, IV 1.5 million units diluted in 100 mL sodium chloride 0.9%, infused over 30–60 minutes. Do not use heparin if streptokinase is given. Hypotension may occur. If it does, reduce the rate of infusion but strive to complete it in < 60 minutes. Streptokinase is antigenic and should not be re- administered in the period of 5 days to 2 years after 1st administration. Severe allergic reactions are uncommon but antibodies which may render it ineffective may persist for years. Note: Refer all suspected or diagnosed cases urgently. 	 Alteplase, IV infusion: Do not exceed 100 mg. if history of onset is less than 6 hours (beyond 6 hours consult a specialist or treat as NSTEMI (see below): Mext 30 Next 60 minutes Bolus minutes minutes >67 kg 15 mg 50 mg 35 mg ≤67 kg 15 mg 0.75 mg/kg 0.5 mg/kg Indications and contraindications are similar to those for streptokinase as below (except prior use of streptokinase is not a contraindication). Indications Contra-indications For acute myocardial infarction with ST elevation or left bundle branch block: maximal chest pain, consult a specialist beyond 6 hours and ongoing chest pain, consult a specialist >6 hours and ongoing chest pain, consult a specialist >6 hours and ongoing chest pain, scensult as treatment, manage with anticoagulants (see section 4.3: NSTEMI) if ongoing ischaemic pain

NOTICE: STREPTOKINASE 1 500 000 IU INJECTION DISCONTINUATION

Indication: Adult Hospital Level STGs and EML, 2019	Current recommendation in STGs and EML				Therapeutic alternative				
	Stre dilui 0.99 Do stre 0 0 0 0 0 0 0 0 0 0 0 0 0	does, reduce the rate of infusion but strive to complete it in < 60 minutes. Streptokinase is antigenic and should not be re-administered in the period of 5 days to 2 years after 1st administration. Severe allergic reactions are uncommon but antibodies which may render it ineffective may persist for years. ptokinase is unavailable: Iteplase, IV infusion: Do not exceed 100 mg.		 o I o I o I (a >67 kg ≤67 kg Indication those for of strep Indication For acute infarction elevation bundle block: - maxin pain i - beyon and co pain, speci 	lase, IV inf Do not exce f history of beyond 6 h is NSTEM Bolus 15 mg 15 mg 15 mg 15 mg ons and co or streptoki tokinase is on with S on or le branc mal ches s ≤6 hours nd 6 hours ngoing ches consult alist ours and n	usion: eed 100 mg. onset is less th nours consult a (see below): Next 30 minutes 50 mg 0.75 mg/kg ntraindications nase as below not a contraind <u>Contra-indi</u> al <u>Absolute:</u> - previous <u>ft</u> - CVA w months, - history st - bleeding month, st - aneurysi a - brain or head i o precedin	an 6 hours specialist or treat Next 60 minutes 35 mg 0.5 mg/kg are similar to (except prior use dication). cations allergy, ithin the last 3 of recent major within the last		
	Bolus minutes minutes >67 15 mg 50 mg 35 mg kg 15 mg 0.75 0.5 kg 0.75 mg/kg mg/kg ○ Indications and contraindications are similar those for streptokinase as above (except that prior use streptokinase is not a contraindication).		0.5 mg/kg e similar to use as prior use of	(see	oagulants section 4.3 EMI) if or	B: <u>Relative</u> (cor - refractor - warfarin - recent treatmer	retinal laser ht, an central venous		

Procurement of alteplase 50mg injection

NSN	Product	Supplier	Contract
180189601	Alteplase; 50mg; Injection; 1 Injection	Ingelheim Pharmaceuticals (Pty) Ltd	HP06- 2021SVP/01

Circular dissemination

Provinces and Healthcare facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees and all other relevant stakeholders.

Kind regards

& Janaroo Tren

MS K JAMALOODIEN CHIEF DIRECTOR: SECTOR-WIDE PROCUREMENT DATE: 10 December 2023